Skip to main content

Plaintiff Seeks To Revive Zimmer Hip Implant Lawsuit

Plaintiff Seeks To Revive Zimmer Hip Implant Lawsuit

Plaintiff Seeks To Revive Zimmer Hip Implant Lawsuit

Introduction

In a September 10 notice of appeal, a plaintiff involved in the Zimmer hip implant litigation has appealed to the 3rd Circuit U.S. Court of Appeals to reinstate her lawsuit, which was dismissed last month by U.S. District Court Judge Edward G. Smith over late filing.

The plaintiff was implanted with Zimmer Inc.’s Kinectiv Technology hip implant system with a VerSys femoral head in 2011. She experienced metallosis, an adverse tissue reaction, allegedly due to the design defects of the hip implant and eventually removed it in 2015. She sued the manufacturer in February 2017 accusing them of failing to provide adequate warning. However, the New Jersey jury rejected her claims as she had crossed the two-year statute of the limitation period.

Zimmer Durom Hip Cup multidistrict litigation was centralized on June 9, 2010, in the U.S District of New Jersey before Judge Susan D. Wigenton as multidistrict litigation, MDL No. 2158 (In Re: Zimmer Durom Hip Cup Products Liability Litigation).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!